A Neko Health investor on the $700M bet to scan your whole body
- ID
- 30485
- Status
- summarized
- Published
- 01 Oct 2026, 4:17 AM
- Fetched
- 01 Oct 2026, 5:31 AM
- Provider
- TechCrunch Startups
- Category
- startup
- Original URL
- https://techcrunch.com/podcast/the-investor-behind-neko-healths-700m-bet-on-scanning-your-whole-body/
- Source URL
- https://techcrunch.com/category/startups/feed/
Summary
- Score
- 3.0
- Created
- 01 Oct 2026, 5:32 AM
- Tags
- Audience
- foundersai_ml_learners
What happened
TechCrunch's Equity podcast episode features Farooq Abbasi, founder and general partner of Preface Ventures and an investor in Neko Health, discussing the company's $700 million raise to build a preventative body-scanning business. The episode covers what Neko's $500 scan actually includes, how the company keeps that price down, why Abbasi sees low primary-care utilization as one of the biggest problems in U.S. healthcare, and his view that some consumer-health startups may be overfunded. The show also notes Midjourney is building its own body scanner and that Function Health has raised significant capital for a preventative-health platform.
Why it matters
This is a podcast promo, not new product or pricing news, so nothing here changes what you build this week. The one reusable number is the $500 scan price and the claim that Neko keeps it down through its own operations — if you are modelling consumer health or diagnostics pricing for a Malaysian or SEA market, that unit-economics question (what a scan must cost to be repeatable without insurance) is the part worth stealing, and the episode reportedly discusses it. Otherwise treat the $700M figure as a funding headline, not a signal about your roadmap.
Discussion angle
Neko's $500 scan is positioned against low U.S. primary-care utilization — does the same wedge exist here, where private GP and panel-clinic economics differ sharply, or is the consumer-pays model a U.S. insurance artifact? Note the episode gives no Malaysian or SEA detail, so this is a hypothesis to debate, not a finding.